%0 Journal Article %A TAKEHITO SHUKUYA %A TOSHIAKI TAKAHASHI %A HIDEYUKI HARADA %A HIROAKI AKAMATSU %A CHIKARA SAKAGUCHI %A HISAO IMAI %A AKIRA ONO %A YUKIKO NAKAMURA %A ASUKA TSUYA %A HIROTSUGU KENMOTSU %A TATEAKI NAITO %A HARUYASU MURAKAMI %A MASAHIRO ENDO %A KAZUHISA TAKAHASHI %A NOBUYUKI YAMAMOTO %T Comparison of Vinorelbine plus Cisplatin and S-1 plus Cisplatin in Concurrent Chemoradiotherapeutic Regimens for Unresectable Stage III Non-small Cell Lung Cancer %D 2012 %J Anticancer Research %P 675-680 %V 32 %N 2 %X Background: Based on the results of phase I/II studies, S-1 plus cisplatin (CDDP) and vinorelbine (VNR) plus CDDP are commonly used chemoradiotherapeutic regimens for the treatment of non-small cell lung cancer(NSCCLC) in Japan. However, there have been no studies that have compared S-1 and CDDP combined with thoracic radiotherapy (TRT) with VNR and CDDP combined with TRT. Patients and Methods: A total of 39 and 50 patients with stage III non-small cell lung cancer (NSCLC) were treated with S-1 and CDDP plus concurrent TRT, or with VNR and CDDP plus concurrent TRT, respectively, between 2002 and 2010. Results: In the S-1 plus CDDP plus TRT group, the median progression-free survival (PFS) and the median overall survival (OS) were 327 days and 1012 days, respectively. In the VNR plus CDDP plus TRT group, the median PFS and the median OS were 328 days and 905 days, respectively. The differences in the PFS and OS were not statistically significant. Grade 3 or more leukopenia and neutropenia were significantly more common in the VNR plus CDDP plus TRT group. Grade 3 or more thrombocytopenia, esophagitis and eruption tended to be more common in the S-1 plus CDDP plus TRT group. Conclusion: Due to the difference in the toxicity profiles of the two combinations, S-1 plus CDDP plus TRT or VNR plus CDDP plus TRT should be selected depending on each patient's baseline characteristics. %U https://ar.iiarjournals.org/content/anticanres/32/2/675.full.pdf